ActRIIB: ALK4-Fc alleviates muscle dysfunction and comorbidities in murine models of neuromuscular disorders
J Li, M Fredericks, M Cannell, K Wang… - The Journal of …, 2021 - Am Soc Clin Investig
Patients with neuromuscular disorders suffer from a lack of treatment options for skeletal
muscle weakness and disease comorbidities. Here, we introduce as a potential therapeutic …
muscle weakness and disease comorbidities. Here, we introduce as a potential therapeutic …
Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy
F Morvan, JM Rondeau, C Zou… - Proceedings of the …, 2017 - National Acad Sciences
The TGF-β family ligands myostatin, GDF11, and activins are negative regulators of skeletal
muscle mass, which have been reported to primarily signal via the ActRIIB receptor on …
muscle mass, which have been reported to primarily signal via the ActRIIB receptor on …
Akt deficiency attenuates muscle size and function but not the response to ActRIIB inhibition
Background Akt is a critical mediator of developmental skeletal muscle growth. Treatment
with a soluble ActRIIB fusion protein (ActRIIB-mFc) increases skeletal muscle mass and …
with a soluble ActRIIB fusion protein (ActRIIB-mFc) increases skeletal muscle mass and …
An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy
E Lach-Trifilieff, GC Minetti, KA Sheppard… - … and cellular biology, 2014 - Am Soc Microbiol
The myostatin/activin type II receptor (ActRII) pathway has been identified to be critical in
regulating skeletal muscle size. Several other ligands, including GDF11 and the activins …
regulating skeletal muscle size. Several other ligands, including GDF11 and the activins …
Activin receptor type IIB inhibition improves muscle phenotype and function in a mouse model of spinal muscular atrophy
M Liu, DW Hammers, ER Barton, HL Sweeney - PloS one, 2016 - journals.plos.org
Spinal muscular atrophy (SMA) is a devastating neurodegenerative disorder that causes
progressive muscle atrophy and weakness. Using adeno-associated virus-mediated gene …
progressive muscle atrophy and weakness. Using adeno-associated virus-mediated gene …
[HTML][HTML] Identification of ligand-selective peptidic ActRIIB-antagonists using phage display technology
K Sakamoto, Y Kanematsu-Yamaki, Y Kamada… - … and Biophysics Reports, 2017 - Elsevier
ActRIIB (activin receptor type-2B) is an activin receptor subtype constitutively expressed in
the whole body, playing a role in cellular proliferation, differentiation, and metabolism. For its …
the whole body, playing a role in cellular proliferation, differentiation, and metabolism. For its …
[HTML][HTML] Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy
The activin receptor type IIB (ActRIIB) is a transmembrane receptor for transforming growth
factor-β superfamily members, including myostatin, that are involved in the negative …
factor-β superfamily members, including myostatin, that are involved in the negative …
[HTML][HTML] Disease-modifying effects of orally bioavailable NF-κB inhibitors in dystrophin-deficient muscle
DW Hammers, MM Sleeper, SC Forbes, CC Coker… - JCI insight, 2016 - ncbi.nlm.nih.gov
Duchenne muscular dystrophy (DMD) is a devastating muscle disease characterized by
progressive muscle deterioration and replacement with an aberrant fatty, fibrous matrix …
progressive muscle deterioration and replacement with an aberrant fatty, fibrous matrix …
Combined Effect of AAV-U7-Induced Dystrophin Exon Skipping and Soluble Activin Type IIB Receptor in mdx Mice
WMH Hoogaars, E Mouisel, A Pasternack… - Human gene …, 2012 - liebertpub.com
Abstract Adeno-associated virus (AAV)-U7–mediated skipping of dystrophin-exon-23
restores dystrophin expression and muscle function in the mdx mouse model of Duchenne …
restores dystrophin expression and muscle function in the mdx mouse model of Duchenne …
ActRIIB blockade increases force‐generating capacity and preserves energy supply in exercising mdx mouse muscle in vivo
N Béchir, E Pecchi, C Vilmen, Y Le Fur… - The FASEB …, 2016 - Wiley Online Library
Postnatal blockade of the activin type IIB receptor (ActRIIB) represents a promising
therapeutic strategy for counteracting dystrophic muscle wasting. However, its impact on …
therapeutic strategy for counteracting dystrophic muscle wasting. However, its impact on …